Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1 5Phase 1/2 4Phase 2/3 3Phase NA 1Phase 3 1

Status

Unknown 3

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Gastrointestinal 1

Conditions

Neoplasm, Residual 1NSCLC 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 98Gemcitabine 66Paclitaxel 62Carboplatin 60Fluorouracil 59Docetaxel 59Capecitabine 59Oxaliplatin 56Cyclophosphamide 54Radiotherapy 50Drug Therapy 46Bevacizumab 38pembrolizumab 35Dexamethasone 33Magnetic Resonance Spectroscopy 32Leucovorin 32Doxorubicin 31Cytarabine 27Etoposide 26Pemetrexed 25Nivolumab 24Methotrexate 24Radiation 20venetoclax 18Vincristine 18apatinib 17Rituximab 17Prednisone 17Letrozole 17Irinotecan 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Tyrosine Kinase Inhibitors × Clear all
NCT03256981 2023-12-26

HALT

Institute of Cancer Research, United Kingdom

Phase 2/3 Unknown
113 enrolled
Thoracic

NSCLC

NCT02794337 2022-04-27

TACE-SBRT

Tata Memorial Hospital

Phase 2/3 Unknown
67 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT03624530 2018-08-10

Effect of Prophylactic TKI Therapy Post-transplants on Ph+ ALL Undergoing Allo-HSCT With MRD Positive Pre-transplants

Nanfang Hospital, Southern Medical University

Phase 2/3 Unknown
82 enrolled
Tumor-Agnostic

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡